BEACON pharmaceuticals Ltd. (BPL), the number 1 oncology company in Bangladesh has launched Crizotinib, the research molecule of Pfizer Oncology, under the brand name of Crizonix. Crizonix is the 1st global generic of Crizotinib.
Crizotinib is the first and only drug of its kind which bagged the FDA approval for the treatment of for both ALK + and ROS-1+ NSCLC patient. It is the only FDA approved treatment for patients with ROS-1 positive NSCLC.
Lung cancer is the leading cause of cancer death in both sexes which is about one-third of all cancer deaths. it has been the goal of BPL to provide an affordable treatment option to everyone, everywhere all around the globe.
“We are trying to support global cancer patient by offering latest drug at affordable price” said Mr. Ebadul Karim, Managing Director of BPL.
“We are getting huge queries from across the world” said Mr.Monjur, Head of Business Development Department, BPL. Earlier BEACON had introduced blockbuster for HEP C drugs which they have exported to 54 countries. “We are hoping to export Crizonix to at least 75 countries. Company is expecting to grab 10 million dollar business by exporting this novel blockbuster drug” –Mr. Monjur added.
Because of the benefits of Patent law which have been made under WTO agreement, BEACON is preparing at 10 more new blockbuster drugs for introduction by 2016.